Dissemination

Where applicable, we seek to present the results of our activities at national and international conferences and to publish in high quality peer-reviewed journals (examples below).


Stevens J et al. Use of a Bayesian mixed treatment meta analysis to support reimbursement decision making of phosphate binder therapy in end-stage renal disease ViH 2009:12(7):A221-37.


World Leading Research

ScHARR received excellent ratings in the 2008 UK Research Assessment Exercise and had by far the largest number of research staff in the Health Services Research unit of assessment in the UK. Furthermore, 55% of activities were assessed as either world leading or internationally excellent.

This combination of scale and quality of health services research made ScHARR the number one UK centre, as measured by the ‘Research Power League Table’ (www.sheffield.ac.uk/content/1/c6/01/46/51/RAE2008_research_capacity_researchresearch.com.pdf).

Teaching

We provide both Masters and short courses relating to health economics (www.sheffield.ac.uk/scharr)

Innovation & Knowledge Transfer

Contact details

Further information about consultancy projects and research areas is available at http://www.sheffield.ac.uk/scharr/consultancy

For an informal chat please contact the HEDS programme director, Roberta Ara:

Email: r.m.ara@sheffield.ac.uk
Tel: +44 (0)114 222 0788

©The University of Sheffield 2011
This leaflet is available in alternative formats
To request a different format:
T: +44(0)114 222 1303
E: disabilityinfo@sheffield.ac.uk
The School of Health and Related Research (ScHARR), based at the University of Sheffield, has been conducting consultancy and knowledge transfer activities for public and private sector clients since 1994. The Health Economics and Decision Science (HEDS) section within ScHARR is one of the largest health economics groups in the world. We have a long track record of providing high quality Health Technology Assessment submissions to the National Institute for Health & Clinical Excellence, the Scottish Medicines Consortium and similar policy decision-making bodies worldwide.

**Health Economic Modelling**

We are world-leading experts in designing and building de novo decision models to evaluate the cost-effectiveness of health care interventions. Model types range from simple decision trees and Markov models to more complex discrete event simulations, depending on project requirements. Models are individually constructed in software such as Microsoft Excel or Simul8.

**Modelling Alongside Clinical Trials**

We offer expertise in developing research methods used to analyse individual patient level data collected during clinical trials.

**Costing Studies**

We conduct analyses exploring resource use, linking costs to clinical variables where applicable to inform economic models.

**Systematic Reviewing**

We deliver high quality systematic reviews of clinical-effectiveness evidence suitable for submission to the National Institute for Health & Clinical Excellence, including both narrative reviews and quantitative meta-analyses. We also perform tailored literature searches to identify model parameters and health utility data.

**Evidence Synthesis**

We conduct both Classical and Bayesian methods of evidence synthesis including network meta-analyses. As part of the Centre for Bayesian Statistics in Health Economics (CHEBS) we can offer innovative solutions to the challenges that arise in evidence synthesis such as heterogeneity, indirect comparisons and baseline risk effects.

**Clinical Trial Simulation**

We conduct Classical clinical trial simulation and Bayesian trial simulation to optimise clinical trial design and determine the probability of a successful trial outcome.

**Health Related Quality of Life**

As internationally recognised experts in this field we have vast experience in the measurement of health state utilities values for use in economic evaluation, including reviews of the appropriateness of existing generic preference-based measures (like EQ-5D and SF-6D), developing new preference-based measures including those more suitable for specific conditions (e.g. Over Active Bladder with the OAB-5D) or patient population (e.g. Children with the CHU-9D www.sheffield.ac.uk/scharr/sections/heds/mvh/paediatric), the use of state-of-the-art techniques to map from various health related quality of life scales onto generic preference-based measures, reviews of health state utility values in different conditions (e.g. Osteoporosis) and methods for adapting values for use in economic models. We are also looking at new methods for valuing health and other benefits of health care (e.g. broader well-being and processes of care) and the social value of a QALY.

**Disease Areas**

We have expertise in a range of clinical areas: Acute coronary syndrome, Age-related macular degeneration, Alcohol, Alzheimer’s, Ankylosing spondylitis, Asthma, Back pain, Breast cancer, Cardiovascular conditions, Colon cancer, Colorectal cancer, Dementia, Depression, Dyskaryosis, Epilepsy, Flushing, Foot ulcers, Immune thrombocytopenic purpura, Incontinence, Influenza, Irritable bowel syndrome, Leg ulcers, Lymph node metastases, Menopause, Mental health problems, Multiple sclerosis, Obesity, Occlusive vascular events, Osteoporosis, Overactive bladder, Prostate cancer, Psoriatic arthritis, Pulmonary hypertension, Renal disease, Rheumatoid arthritis, Schizophrenia, Sexual health, Surgical procedures in sex reassignment, Type 2 diabetes, Type 1 diabetes, Vaccination scheduling, Venous ulcers.

**Staff**

The multidisciplinary staff include:

- 26 cost effectiveness modellers
- 14 economists and patient reported outcome specialists
- 29 systematic reviewers and information specialists
- 8 statisticians and others